Tenecteplase

Generic Name: Tenecteplase

Brand Names: Metalyse, Tnkase

Drug Type: Biotech

Chemical Formula: -

CAS Number: 191588-94-0

Unique Ingredient Identifier: WGD229O42W

Background: Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease doma...

Indication: 用于溶栓治疗。

Associated Conditions: Cardiovascular Mortality

Associated Therapies: -

Clinical Trials

A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

Phase 3

Completed

Conditions: Stroke, Acute

Interventions: Drug: Tenecteplase
Drug: Antiplatelet treatment

First Posted Date: 2015-03-25

Last Posted Date: 2024-08-16

Lead Sponsor: University of Calgary

Target Recruit Count: 886

Registration Number: NCT02398656

Locations: 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
🇬🇧
Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom
🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

and more 58 locations

Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase
Drug: Tissue Plasminogen Activator

First Posted Date: 2015-03-13

Last Posted Date: 2018-03-30

Lead Sponsor: Neuroscience Trials Australia

Target Recruit Count: 202

Registration Number: NCT02388061

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
Gosford Hospital, Gosford, New South Wales, Australia
🇦🇺
John Hunter Hospital, Newcastle, New South Wales, Australia

and more 15 locations

Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion

Phase 2

Withdrawn

Conditions: Nervous System Disorders
Cerebral Artery

Interventions: Drug: rt-PA
Drug: tenecteplase

First Posted Date: 2015-01-14

Last Posted Date: 2018-06-21

Lead Sponsor: University Hospital Center of Martinique

Registration Number: NCT02338466

Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI

Phase 3

Conditions: Myocardial Infarction

Interventions: Drug: Recombinant staphylokinase
Drug: Tenecteplase

First Posted Date: 2014-11-26

Last Posted Date: 2014-11-26

Lead Sponsor: Supergene, LLC

Target Recruit Count: 392

Registration Number: NCT02301910

Locations: 🇷🇺
Research Institute of Complex Problems of Cardiovascular diseases, Kemerovo, Russian Federation
🇷🇺
Mariinsk City Hospital, St.-Petersburg, Russian Federation
🇷🇺
Institute of Cardiology, Tomsk, Siberia, Russian Federation

and more 12 locations

A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Alteplase
Drug: Tenecteplase
Drug: Streptokinase

First Posted Date: 2014-07-08

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02182011

Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)

Phase 2

Withdrawn

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase
Drug: Alteplase

First Posted Date: 2014-07-02

Last Posted Date: 2015-09-23

Lead Sponsor: Reza Behrouz, DO

Registration Number: NCT02180204

Locations: 🇺🇸
The Ohio State University College of Medicine, Columbus, Ohio, United States

Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke

Phase 3

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase
Drug: Alteplase

First Posted Date: 2013-09-25

Last Posted Date: 2017-05-09

Lead Sponsor: Lars Thomassen

Target Recruit Count: 1050

Registration Number: NCT01949948

Locations: 🇳🇴
Molde Hospital, Molde, Norway
🇳🇴
Haugesund Hospital, Haugesund, Norway
🇳🇴
Baerum Hospital, Rud, Norway

and more 10 locations

TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase

First Posted Date: 2012-07-31

Last Posted Date: 2020-11-25

Lead Sponsor: University of Calgary

Target Recruit Count: 50

Registration Number: NCT01654445

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)

Phase 2

Completed

Conditions: Stroke

Interventions: Drug: Tenecteplase
Drug: alteplase

First Posted Date: 2011-11-17

Last Posted Date: 2018-08-03

Lead Sponsor: NHS Greater Glasgow and Clyde

Target Recruit Count: 104

Registration Number: NCT01472926

Locations: 🇬🇧
Southern General Hospital, Glasgow, Scotland, United Kingdom

STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction

Phase 3

Completed

Conditions: Myocardial Infarction

Interventions: Drug: enoxaparin
Procedure: primary PCI
Procedure: catheterisation
Drug: tenecteplase
Drug: clopidogrel

First Posted Date: 2008-02-26

Last Posted Date: 2019-08-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1899

Registration Number: NCT00623623

Locations: 🇮🇹
1123.28.39001A Boehringer Ingelheim Investigational Site, Monza, Italy
🇫🇷
1123.28.3329A Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France
🇫🇷
1123.28.3329C Boehringer Ingelheim Investigational Site, Aubervilliers Cedex, France

and more 197 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy